ArticleJournal of biomedical optics2025
Elucidating the effect of tumor and background region-of-interest selection on the performance metrics used to assess fluorescence imaging.
Article in Journal of biomedical optics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
Significance: The development of fluorescent contrast agents for fluorescence-guided surgery is rapidly growing with many agents being designed for tumor visualization. Although efforts have been made to standardize the sensitivity of imaging system detection methods for these contrast agents, guidelines to evaluate tumor contrast agent performance, especially the selection of tumor and background regions of interest (ROIs), differ widely across studies. We examine how systematically changing tumor and background ROIs affects common metrics of contrast agent performance. Aim: We aim to elucidate the influence of changing tumor and background brain regions of interest on fluorescent contrast agent performance. Approach: Mice with orthotopic brain tumors were administered a non-targeted fluorescent contrast agent 40 min prior to sacrifice and then imaging of the specimen using whole-body fluorescence cryotomography. The reconstructed 3D fluorescence volumes were then used to compute contrast and diagnostic performance metrics [tumor-to-background brain ratio (TBR), contrast-to-noise (CNR), and area under the receiver operating characteristic curve (AUC)] while systematically varying tumor and normal brain ROIs. Results: ROI selection had a significant impact on the reported values of metrics used to evaluate fluorescence imaging strategies. The use of contralateral background ROIs, commonly used in the field, produced elevated and favorable performance metric values. These metrics decreased as background ROIs approached regions adjacent to the tumor boundary. TBR changed by a factor of 5, CNR by a factor of 7, and AUC by over 10%, largely depending on the proximity of the background region to the tumor. Conclusions: Background ROI selection has a significant impact on the performance metrics commonly used in the field. Future studies should carefully select ROIs relevant to the application and include clear descriptions of these regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.